한글목차

엔트렉티닙(일명 로즐리트렉)은 암 치료의 새로운 접근법을 제시하는 종양 진단 약물입니다. 엔트렉티닙은 선택적 티로신 키나아제 억제제로 TRKA/B/C 및 ROS1 단백질의 키나아제 활성을 억제하도록 설계됐습니다. 현재 고형암 환자를 대상으로 한 임상 2상 바스켓 임상(STARTRK-2)을 진행 중이며, 2024년 12월까지 완료될 예정입니다.

앞으로 몇 년동안 난소암 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, entrectinib의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 난소암에 대한 다른 신흥 제품들이 엔트렉티닙과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 난소암 치료제 엔트렉티닙(Entrectinib) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 난소암에서의 엔트렉티닙 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 엔트렉티닙 시장 평가

• 난소암 치료제 엔트렉티닙 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 난소암 치료제 엔트렉티닙 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Entrectinib Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about entrectinib for ovarian cancer in the seven major markets. A detailed picture of the entrectinib for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the entrectinib for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the entrectinib market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

Entrectinib (also known as Rozlytrek) is a tumor-agnostic medicine that represents a new approach to treating cancer. It is a selective tyrosine kinase inhibitor designed to inhibit the kinase activity of the TRKA/B/C and ROS1 proteins, whose activating fusions drive proliferation in certain types of cancer. It is currently being investigated in a Phase II basket clinical trial (STARTRK-2) for the potential treatment of a patient with solid tumors that is estimated to be completed by December 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the entrectinib description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on entrectinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the entrectinib research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around entrectinib.
• The report contains forecasted sales of entrectinib for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for entrectinib in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Entrectinib Analytical Perspective by DelveInsight

• In-depth Entrectinib Market Assessment

This report provides a detailed market assessment of entrectinib for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• Entrectinib Clinical Assessment

The report provides the clinical trials information of entrectinib for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence entrectinib dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to entrectinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of entrectinib in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of entrectinib from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the entrectinib in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of entrectinib?
• What is the clinical trial status of the study related to entrectinib in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the entrectinib development?
• What are the key designations that have been granted to entrectinib for ovarian cancer?
• What is the forecasted market scenario of entrectinib for ovarian cancer?
• What are the forecasted sales of entrectinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to entrectinib for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. Entrectinib Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Entrectinib Market Assessment

• 5.1. Market Outlook of Entrectinib in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Entrectinib in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Entrectinib in the United States for ovarian cancer
  • 5.3.2. Market Size of Entrectinib in Germany for ovarian cancer
  • 5.3.3. Market Size of Entrectinib in France for ovarian cancer
  • 5.3.4. Market Size of Entrectinib in Italy for ovarian cancer
  • 5.3.5. Market Size of Entrectinib in Spain for ovarian cancer
  • 5.3.6. Market Size of Entrectinib in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of Entrectinib in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options